The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The Phase II CHEPA trial: brentuximab vedotin, CHP, and etoposide in newly diagnosed CD30+ PTCL
Marek Trněný, MD, Charles University Hospital, Prague, Czech Republic, discusses the Phase II CHEPA trial (NCT05006664), which investigates the efficacy of brentuximab vedotin combined with intensified chemotherapy (etoposide plus CHP) in patients with newly diagnosed CD30-positive peripheral T-cell lymphoma (PTCL). Prof. Trněný highlights that the CHEPA regimen has shown promising results, with a high complete remission rate, translating into encouraging 2-year progression-free survival (PFS) and overall survival (OS) rates. In patients with anaplastic large cell lymphoma, the data were especially exciting: at a median follow-up of 19 months, the 18-month PFS and OS were both 100%. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The CHEPA study is the study which is aiming to increase the effectiveness of the combination of the antibody drug conjugate brentuximab vedotin plus intensified chemotherapy which is based on the ECHELON-2 data which has demonstrated that Brentuximab vedotin plus CHP is better compared to the CHOP regimen but we know that the CHOP regimen is very probably less effective compared to the CHOEP, it means intensified regimen from the history, from the past...
The CHEPA study is the study which is aiming to increase the effectiveness of the combination of the antibody drug conjugate brentuximab vedotin plus intensified chemotherapy which is based on the ECHELON-2 data which has demonstrated that Brentuximab vedotin plus CHP is better compared to the CHOP regimen but we know that the CHOP regimen is very probably less effective compared to the CHOEP, it means intensified regimen from the history, from the past. So we have been trying to combine Brentuximab vedotin, anti-CD30 antibody drug conjugate plus intensified chemotherapy CHEP. This is the CHEPA trial, the CHEPA regimen. And we have recruited 33 patients who were able to get all six cycles of the chemotherapy. So it means the CHEPA regimen. At the end, the complete remission rate, which was the primary endpoint, was 76%, and it has been translated into promising progression-free survival with two years probability of 78% for PFS and 90% for overall survival.
It could be quite important because we know that the BV-CHP doesn’t answer for everybody. So we need to do more. And this combination of the antibody-drug conjugate plus intensified chemotherapy has been shown to be effective, has been shown to be safe. So it means that for the young patient, poor risk patient, it brings the chance to get the remission, to undergo the stem cell consolidation, etc. So I think that it could impact the younger population with the poor risk factors and especially anaplastic large cell lymphoma. So 100% two-year PFS and the 100% overall survival at two years. So it’s fantastic, isn’t it?
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
